But several patient advocacy groups opposed the bill, citing safety concerns.
Those groups take money from EpiPen’s manufacturer Mylan. They company also submitted a letter in opposition to the bill.
EpiPens currently dominate the market thanks in part to laws that restrict pharmacists from substituting alternative injectors. The cost of EpiPens have enraged some consumers, who complain they have little choice but to pay as much as $600 for a two-pack of the life-saving drug.
"It's really just giving the pharmacist the ability to provide a cheaper generic option for epinephrine for a patient," said state Rep.
Niraj Antani, R-Miami Twp., a member of the health committee. "One company shouldn't have a monopoly over providing a life-saving drug."
Now that the committee has passed the bill, it’s up to the full House to take it up for a vote.
MORE FROM PRESCRIPTION DRUG PRICES SERIES:
Consumers kept in the dark over drug pricing
Read the fine print, prescription drug discounts may contain a catch
Who’s really controlling your drug prices? 5 things to know
Dayton man lead plaintiff in drug suit alleging price-gouging